Stocktoria
VivoSim Labs, INC. VIVS
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-08-02
VivoSim Labs, INC. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $131,000 | $144,000 | $109,000 | $370,000 | $1.5M | $0 | $2.2M | $3.1M | $4.6M | $4.2M |
| R&D expense | $4.2M | $5.0M | $5.5M | $8.9M | $3.3M | $1.1M | $5.3M | $14.8M | $18.0M | $19.5M |
| SG&A expense | $7.4M | $7.7M | $9.7M | $9.2M | $9.7M | $15.7M | $18.1M | $15.1M | $20.9M | $22.3M |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M | -$11.5M | -$16.8M | -$21.5M | -$27.3M | -$35.3M | -$38.6M |
| Interest expense | — | — | — | — | — | — | — | — | — | $0 |
| Income tax | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $3,000 | $2,000 | $23,000 |
| Net income | -$13.8M | -$2.5M | -$14.7M | -$17.3M | -$11.4M | -$16.8M | -$18.7M | -$26.6M | -$34.8M | -$38.4M |
| EPS (diluted) | $-5.35 | $-1.70 | $-19.25 | $-1.98 | $-1.32 | — | — | — | — | — |
| Operating cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.4M | -$8.5M | -$13.3M | -$14.9M | -$20.4M | -$28.9M | -$29.2M |
| Free cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.8M | -$8.9M | -$13.7M | -$14.9M | -$20.5M | -$29.1M | -$30.5M |
| Cash & equivalents | $5.0M | $11.3M | $2.9M | $15.3M | $28.7M | $37.4M | $27.4M | $36.5M | $43.7M | $62.8M |
| Inventory | — | $0 | $297,000 | $0 | — | — | $0 | $490,000 | $842,000 | $550,000 |
| Total assets | $7.4M | $14.7M | $6.3M | $20.3M | $33.3M | $39.9M | $28.4M | $40.6M | $49.8M | $69.2M |
| Total liabilities | $8.5M | $4.2M | $2.7M | $5.0M | $3.1M | $721,000 | $1.8M | $4.3M | $5.2M | $6.8M |
| Shareholders' equity | -$1.1M | $10.5M | $3.6M | $15.3M | $30.2M | $39.2M | $26.6M | $36.3M | $44.6M | $62.4M |
Growth · year-over-year · Revenue CAGR -32%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -9.0% | +32.1% | -70.5% | -75.3% | — | -100.0% | -29.0% | -32.8% | +8.8% | +185.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.